125 related articles for article (PubMed ID: 29977052)
1. The evolution of adaptiveness: balancing speed and evidence.
Eichler HG; Barker R; Bedlington N; Bouvy JC; Broekmans AW; Bucsics A; Cerreta F; Corriol-Rohou S; Granados A; Le Cam Y; Schuurman A
Nat Rev Drug Discov; 2018 Dec; 17(12):845-846. PubMed ID: 29977052
[No Abstract] [Full Text] [Related]
2. Priced out of the UK market.
Moran N
Nat Biotechnol; 2008 Feb; 26(2):151-4. PubMed ID: 18259163
[No Abstract] [Full Text] [Related]
3. Market watch: Top drugs and companies by sales in 2017.
Urquhart L
Nat Rev Drug Discov; 2018 Mar; 17(4):232. PubMed ID: 29588516
[No Abstract] [Full Text] [Related]
4. Repackaging.
Prescrire Int; 2016 Jan; 25(167):10. PubMed ID: 26942252
[No Abstract] [Full Text] [Related]
5. Biotech drug market steadily expands.
Lawrence S
Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
[No Abstract] [Full Text] [Related]
6. Deconstructing Myogen's market cap.
Ransom J
Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
[No Abstract] [Full Text] [Related]
7. A change in the market--investing in diagnostics.
Batchelder K; Miller P
Nat Biotechnol; 2006 Aug; 24(8):922-6. PubMed ID: 16900131
[No Abstract] [Full Text] [Related]
8. Making the move into drug sales.
Willerroider M
Nature; 2004 Jul; 430(6998):486-7. PubMed ID: 15269778
[No Abstract] [Full Text] [Related]
9. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.
Buckely M
Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760
[No Abstract] [Full Text] [Related]
10. Health care and the pharmaceutical industry.
Schwartz JB
J Parenter Sci Technol; 1993; 47(5):191. PubMed ID: 8263657
[No Abstract] [Full Text] [Related]
11. Pricing of pharmaceuticals is becoming a major challenge for health systems.
Morgan SG; Bathula HS; Moon S
BMJ; 2020 Jan; 368():l4627. PubMed ID: 31932289
[No Abstract] [Full Text] [Related]
12. Comments on "Presidential address: advocacy as leadership".
Clary C; Loebel A; Lombardo I; Alphs L; Binneman B; Vanderburg D; Warrington L; Parsons B; Fogel I; Herman B; Roberts H; Templeton H; Hughes D; Chappell P; Feltner D; Tobias K; Watsky E; Ramey T; Rappard F
Am J Psychiatry; 2007 Feb; 164(2):346; author reply 346. PubMed ID: 17267802
[No Abstract] [Full Text] [Related]
13. The European value-pricing game.
McGuire A
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):5-6. PubMed ID: 22280188
[No Abstract] [Full Text] [Related]
14. Crossing the fourth hurdle.
Rawlins MD
Br J Clin Pharmacol; 2012 Jun; 73(6):855-60. PubMed ID: 22404227
[TBL] [Abstract][Full Text] [Related]
15. Europe on the brink of direct-to-consumer drug advertising.
Lancet; 2002 May; 359(9319):1709. PubMed ID: 12049853
[No Abstract] [Full Text] [Related]
16. European Generic Medicines Association (EGA)--16th Annual Conference.
Kennedy B
IDrugs; 2010 Aug; 13(8):530-3. PubMed ID: 20721822
[TBL] [Abstract][Full Text] [Related]
17. [From the very valuable therapy, to the high cost of a new drug: a growing hiatus].
Scheen AJ
Rev Med Suisse; 2005 Aug; 1(30):1931-2. PubMed ID: 16200935
[No Abstract] [Full Text] [Related]
18. European collaboration on relative effectiveness will move into the next phase.
Goettsch W
J Comp Eff Res; 2013 Jan; 2(1):5-6. PubMed ID: 24236514
[No Abstract] [Full Text] [Related]
19. European Commission's inquiry into the pharmaceuticals sector.
Ager B
Lancet; 2009 Nov; 374(9704):1819; author reply 1819-20. PubMed ID: 19944861
[No Abstract] [Full Text] [Related]
20. The people vs patents.
New Sci; 2002 Jul; 175(2351):3. PubMed ID: 12625337
[No Abstract] [Full Text] [Related]
[Next] [New Search]
